Guillaume Bergthold
Executive Director, Clinical Development Daiichi Sankyo
Guillaume is a pediatric hematologist/oncologist by training. He has more than 15 years experience in oncology clinical, translational and drug development space. He works at Daiichi-Sankyo as Global Clinical Lead for R-DXd (CDH6 ADC) and is based in France DS office. Prior joining Daiichi-Sankyo, Guillaume worked at Roche Genentech (Basel) in oncology clinical development (pediatric and adult).
Seminars
Tuesday 24th February 2026
Laying Out Analysis of Raludotatug Deruxtecan Dose Optimisation in Patients with Platinum-Resistant Ovarian Cancer
11:00 am
- Overviewing R-DXd design and mechanism of action
- Presenting clinical activity of R-DXd in patients with platinum-resistant ovarian cancer (PROC) from Phase I and Phase II/III REJOICE-Ov01 study
- Exploring the outcome of dose optimisation analysis of R-DXd in patients with PROC
